Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net margin is calculated as Net Income divided by its Revenue. AtriCure's Net Income for the
three
months ended in Mar. 2026 was €0.1 Mil. AtriCure's Revenue for the
three
months ended in Mar. 2026 was €122.2 Mil. Therefore, AtriCure's net margin for the quarter that ended in Mar. 2026 was 0.08%.
The historical rank and industry rank for AtriCure's Net Margin % or its related term are showing as below:
FRA:A5I'
s Net Margin % Range Over the Past 10 Years
Min: -23.32 Med: -12.27 Max: 18.3
Current: -0.83
FRA:A5I's Net Margin % is ranked worse than 54.78% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs FRA:A5I: -0.83
AtriCure (FRA:A5I) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
AtriCure Net Margin % Related Terms
AtriCure Net Margin % Historical Data
* Premium members only.
The historical data trend for AtriCure's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:A5I vs KMTS, STAA, BLFS: Net Margin % Comparison
For the Medical Instruments & Supplies subindustry, AtriCure's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AtriCure Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AtriCure's Net Margin % distribution charts can be found below:
* The bar in red indicates where AtriCure's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AtriCure (FRA:A5I) has a Net Margin % of 0.08% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on AtriCure and its competitors. According to the industry distribution chart, AtriCure ranks #447 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 54.8%.
Is AtriCure's Net Margin % too high?
AtriCure's current Net Margin % is 0.08%. The Medical Devices & Instruments industry median Net Margin % is 2.07. AtriCure's value of 0.08% is 96.1% below this industry median. Based on the distribution chart, AtriCure ranks #447 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, AtriCure has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does AtriCure's Net Margin % compare to KMTS and STAA?
According to the Medical Devices & Instruments industry distribution chart, AtriCure ranks #447 out of 816 companies for Net Margin %. This places AtriCure in the lower half of its industry. The industry median Net Margin % is 2.07. AtriCure's value of 0.08% is 96.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AtriCure's current Net Margin % of 0.08% is 96.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on AtriCure and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AtriCure's current Net Margin % is 0.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AtriCure stock overvalued right now?
AtriCure (FRA:A5I) has a current Net Margin % of 0.08%. The stock's GF Value™ is €34.78, compared to a current price of €30.40 — trading 12.6% below its estimated fair value. The current Net Margin % is 0.08% and 96.1% below the Medical Devices & Instruments industry median of 2.07. AtriCure's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For AtriCure (FRA:A5I), the current Net Margin % is 0.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AtriCure (FRA:A5I) Overvalued in 2026?
Based on GuruFocus' analysis, AtriCure stock appears to be undervalued.
The current stock price of €30.40 is trading 12.6% below its estimated GF Value™ of €34.78.
Key valuation signals for FRA:A5I:
Net Margin %: 0.08%
GF Value™: €34.78 vs. price of €30.40 (12.6% below fair value)
Industry Position: 96.1% below the Medical Devices & Instruments median (#447 of 816)
No single metric tells the full story. See the FRA:A5I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
78GF Score
Get the complete analysis for FRA:A5I
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:A5I has been successfully added to your 
